# Metformin Plus Irinotecan for Refractory Colorectal Cancer

> **NCT01930864** · PHASE2 · UNKNOWN · sponsor: **Barretos Cancer Hospital** · enrollment: 41 (estimated)

## Conditions studied

- Colorectal Neoplasms
- Adenocarcinoma

## Interventions

- **DRUG:** metformin
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT01930864
- **Lead sponsor:** Barretos Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2017-06-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01930864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01930864, "Metformin Plus Irinotecan for Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01930864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*